Leerink Partners Predicts Atyr PHARMA FY2024 Earnings

On February 18th, analysts from Leerink Partners released their earnings estimates for Atyr PHARMA INC (NASDAQ:ATYR) for the fiscal year 2024. The report, penned by analyst F. Khurshid, forecasts a loss of earnings per share (EPS) of ($0.89) for Atyr PHARMA in the upcoming year. In addition to this, Leerink Partners has assigned a “Strong-Buy” rating to the stock.

The consensus estimate among analysts for Atyr PHARMA’s full-year earnings currently sits at a loss of ($0.91) per share. Furthermore, the firm provided specific quarterly earnings projections for Atyr PHARMA, which include: a projected loss of ($0.21) EPS for Q4 2024, a loss of ($0.21) EPS for Q1 2025, a loss of ($0.22) EPS for Q2 2025, a small loss of ($0.08) EPS for Q3 2025, and a loss of ($0.21) EPS for Q4 2025. As for future earnings, they predict a loss of ($0.71) EPS for FY2025, ($0.56) EPS for FY2026, followed by a turnaround with $0.16 EPS in FY2027, $1.29 EPS in FY2028, and $1.82 EPS in FY2029.

Other research firms have also recently made their own evaluations regarding Atyr PHARMA. HC Wainwright reaffirmed a “buy” rating with a price target of $35.00 for Atyr PHARMA’s shares in a report released on December 10th. On the same day, Leerink Partners initiated coverage with an “outperform” rating and a price target of $16.00. Meanwhile, Cantor Fitzgerald also began coverage on Atyr PHARMA, giving it an “overweight” rating. Currently, six analysts have issued a buy rating, while one has given a strong buy recommendation. Data from MarketBeat.com indicates that Atyr PHARMA holds a consensus rating of “Buy” along with a consensus price target of $18.60.

Atyr PHARMA Trading Update

As of the latest trading session, shares of Atyr PHARMA (NASDAQ:ATYR) opened lower by 2.5% at a price of $4.32. The company has a market capitalization of approximately $362.63 million and a price-to-earnings ratio of -4.60. The stock has a beta of 1.10, which indicates a higher volatility to market movements. Its debt-to-equity ratio is 0.02, and it maintains a solid liquidity position with a quick ratio of 5.41 and a current ratio of 5.41. Over the past year, Atyr PHARMA has seen its stock price fluctuate, recording a low of $1.42 and a high of $4.66. Currently, it has a fifty-day moving average of $3.61 and a 200-day moving average of $2.87.

Institutional Investor Activity

Recent changes in ownership of Atyr PHARMA stock indicate interest from institutional investors. Some notable transactions include Group One Trading LLC acquiring a new stake worth approximately $26,000 in the fourth quarter, and Alterna Wealth Management Inc. purchasing shares valued at around $36,000. Other large investors, such as Victory Capital Management Inc. and Raymond James Financial Inc., have also made investments in Atyr PHARMA with stake values of $37,000 and $39,000, respectively. Overall, institutional ownership accounts for 61.72% of the company’s stock.

About Atyr PHARMA

Atyr Pharma, Inc. is dedicated to the discovery and development of innovative medicines focusing on novel biological pathways. Its product pipeline includes several promising candidates such as ATYR1923, ATYR2810, NRP2 monoclonal antibodies (mAbs), and AARS-1 and DARS-1 therapeutics. Founded on September 8, 2005, by Paul Schimmel, Xiang-Lei Yang, and Bruce Beutler, the company is based in San Diego, California.

Earnings, Stocks, Analyst